ライフサイエンスコーパス: parasitemia

1 lso protects against asymptomatic infection (parasitemia).

2 hanced Th1 immune response that reduced peak parasitemia.

3 repeat CHMI at 59 weeks, and none developed parasitemia.

4 hanced Th1 immune response that reduced peak parasitemia.

5 mmunized and -challenged mice rendered lower parasitemia.

6 rug treatment, correlating with clearance of parasitemia.

7 during malaria and associated with elevated parasitemia.

8 changes in the levels of both thioethers and parasitemia.

9 ssociated with increasing age and concurrent parasitemia.

10 nly misdiagnosed in patients with incidental parasitemia.

11 travelers, O-iRBCs peaked at 107.7% initial parasitemia.

12 ligand PfRh5 was the best predictor of donor parasitemia.

13 No association was identified with parasitemia.

14 als, making it difficult to detect low level parasitemia.

15 e of malaria; and prevalence of asymptomatic parasitemia.

16 CH mice results in a significant increase in parasitemia.

17 s of immune compromise, and risk of incident parasitemia.

18 nd even a lack of progression to blood-stage parasitemia.

19 arly induction of IFN-gamma and reduction in parasitemia.

20 om delay to PCR and microscopy detections of parasitemia.

21 ubsets was directly associated with the peak parasitemia.

22 gion was performed for children with asexual parasitemia.

23 -10 responses, younger age, and asymptomatic parasitemia.

24 r among older children and those with active parasitemia.

25 tions could not predict spatial variation in parasitemia.

26 spatial variation observed in prevalence and parasitemia.

27 nd immune cell activation during the peak of parasitemia.

28 than AL, resulting in delayed recurrence of parasitemia.

29 (PCR), 7 recipients developed PCR-detectable parasitemia.

30 ents because of its higher risk of recurrent parasitemia.

31 m parasites, whereas TMP-SMX prevents patent parasitemia.

32 mains controversial, because it may increase parasitemia.

33 mic effect that exposure to bites has on the parasitemia.

34 ith antimicrobial treatment and clearance of parasitemia.

35 with asymptomatic carriage and undetectable parasitemia.

36 osis, including clearance of Babesia microti parasitemia.

37 and all correlated with age, independent of parasitemia.

38 resulting in impaired control of persistent parasitemia.

39 trine exposure is a determinant of recurrent parasitemia.

40 , sex, Ebola viremia, and Plasmodium species parasitemia.

41 hamsters and the subsequent examination for parasitemia.

42 -infected individuals, correlated with lower parasitemia.

43 to identify and quantify low-density malaria parasitemias.

44 displayed fewer variants compared to initial parasitemias.

45 gnificantly decreased the odds of subsequent parasitemia (23% decrease, P < .001) and subsequent seve

46 at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine grou

47 assays/child), ID reduced the prevalence of parasitemia (6.6-fold), hyperparasitemia (24.0-fold), an

48 Of 270 children, 140 (52%) had peripheral parasitemia, 80 (30%) had malaria retinopathy, and 164 (

49 vity with significant effects on liver stage parasitemia, a most welcome feature for any new class of

50 UIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chimeric pa

51 adult patients with severe malaria and high parasitemia admitted to a referral hospital in Banglades

52 ine of nine CPS-immunized subjects developed parasitemia after blood-stage challenge, with identical

53 tion, we found that concurrent P. falciparum parasitemia also increases the likelihood of the first a

54 en the respective prevalence of asymptomatic parasitemia among children was 81 and 15 percent by micr

55 t alter risks of clinical malaria or malaria parasitemia among school children and that school-based

56 In vivo, a decrease in parasitemia and an increase in survival of mice infected

57 isodes per person-year and the prevalence of parasitemia and anemia was 38% and 20%, respectively.

58 ent risk factors for severe malaria included parasitemia and angiopoietin-2 in knowlesi malaria, and

59 d microglial activation, besides controlling parasitemia and antigen-specific T-cell activation.

60 erstanding the role of S. mansoni on malaria parasitemia and antimalarial immune responses using Plas

61 In malaria holoendemic settings, decreased parasitemia and clinical disease is associated with age

62 modium berghei PbSEA-1 significantly reduced parasitemia and delayed mortality after lethal challenge

63 ax malaria patients with different levels of parasitemia and during the acute and convalescent phases

64 ostinfection, C57BL/6 mice still had chronic parasitemia and efficiently controlled homologous and he

65 Microscopic parasitemia and expression of the immunoregulatory marke

66 al, and cord blood were examined for malaria parasitemia and Hb concentration in a cross-section of 3

67 a and symptomatic cardiomyopathy (SYL), mild parasitemia and high tissue tropism (COL), to no pathoge

68 like E3 ubiquitin ligase (Pyheul) influences parasitemia and host mortality.

69 l death and their relationship to control of parasitemia and host mortality.

70 These chalcones also showed reduction in parasitemia and increased survival time of Swiss mice in

71 and good correlation of antigen levels with parasitemia and its clearance after drug treatment.

72 a MEK1/2 inhibitor approach controls malaria parasitemia and mitigates pathogenic effects on host org

73 th recombinant IL-12 significantly decreased parasitemia and mortality.

74 +) cells, IFN-gamma, and NO, on the level of parasitemia and parasite clearance during acute babesios

75 and dendritic cells, as well as blood-stage parasitemia and parasite-induced IFN-gamma.

76 ium chabaudi offers the best protection from parasitemia and pathology in reinfection cases, correlat

77 d-type (WT) mice, as evidenced by lower peak parasitemia and prolonged survival.

78 severity than P. falciparum (P = .020); only parasitemia and schizontemia >10% independently predicte

79 , when isolated during the period of maximum parasitemia and shortly thereafter, the dendritic cells

80 rentiation program on the ability to control parasitemia and susceptibility to ECM disease during blo

81 ehavior in a murine model, ranging from high parasitemia and symptomatic cardiomyopathy (SYL), mild p

82 SOCS2 KO mice, there was a reduction in both parasitemia and the expression of interferon-gamma (IFN-

83 e virus and examine the role of the virus in parasitemia and the pathogenesis of leishmaniasis.

84 eins in bronchoalveolar lavage fluid, higher parasitemia and tissue parasite burden, and increased nu

85 CoPP reduced parasitemia and tissue parasitism, while an inhibitor of

86 f 24 hours, a direct correlation between the parasitemia and volatile levels was revealed.

87 ice exhibited compromised ability to control parasitemia and were susceptible to death.

88 Differences in characteristics of parasitemias and drug resistance polymorphisms by CPT st

89 pared with Cd36(-/-) mice, WT mice had lower parasitemias and were resistant to death.

90 arkable protection against clinical malaria, parasitemia, and anemia in schoolchildren living in a hi

91 nate and adaptive immune responses, controls parasitemia, and blocks pathogenesis.

92 tection from subsequent clinical malaria and parasitemia, and fewer blood-stage specific CD4(+) T cel

93 ction (PCR) were used to detect asymptomatic parasitemia, and hotspots were detected using the spatia

94 r, these tests often miss cases of low-level parasitemia, and PfHRP-II tests can give false-negative

95 s for death were renal impairment, acidosis, parasitemia, and plasma PfHRP2 concentration.

96 nsity and positivity correlated closely with parasitemia, and population gametocyte prevalence decrea

97 7145 children, 1150 had microscopic asexual parasitemia, and sequencing was performed in 685, of who

98 t is observed following recrudescent asexual parasitemia, and these gametocytes are again refractory

99 Population-level survey data on parasitemia are limited and traditionally exclude adults

100 Using Pf-iRBCs at 0.1% parasitemia as a testing sample, the microfluidic deform

101 10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy.

102 Six of 6 infectivity controls developed parasitemia as expected.

103 were protected against the establishment of parasitemia, as assessed by the molecular force of infec

104 olones were efficacious for the reduction of parasitemia at >99% after 6 days.

105 38 (78%) children had a >/= 99% reduction in parasitemia at 24 h compared to 263/331 (79%) receiving

106 ortion of children with >/= 99% reduction in parasitemia at 24 h from admission values, measured by m

107 /333 (74%) children had >/= 99% reduction in parasitemia at 24 h; hence, non-inferiority of this regi

108 children clearing >/= 99% of their admission parasitemia at 24 hours.

109 ART duration, 4.5 years), 5% had detectable parasitemia at baseline.

110 ted with subsequent microscopically detected parasitemia at days 28 or 42.

111 h a 70% reduction of harboring P. falciparum parasitemia at the heterozygous state (odds ratio [OR] f

112 Log-rank test was used to compare time-to-parasitemia between interventions.

113 el of visceral leishmaniasis, reducing liver parasitemia by 37% when given by the intraperitoneal rou

114 , but reduced the prevalence of asymptomatic parasitemia by 54% (95% CI, 47%-60%, P < .0001).

115 , P < .0001), the prevalence of asymptomatic parasitemia by 94% (95% CI, 92%-96%, P < .0001), and the

116 Three patients (2.8%) with recurrent parasitemia by day 28 in the CQ arm were noted to have d

117 lass of antimalarial drugs that can suppress parasitemia by inhibiting a host target that cannot be m

118 and eighty-two inhabitants were screened for parasitemia by nested polymerase chain reaction (nPCR).

119 et of cytokines/chemokines and the levels of parasitemia by quantitative PCR in the circulation of ne

120 loped ARDS and presented negative peripheral parasitemia by the time of death, scattered parasitized

121 T. cruzi infection, as evidenced by reduced parasitemia, cardiac tissue inflammation, and parasite b

122 ymptomatic infections, with no difference in parasitemia characteristics.

123 locytosis was evident despite differences in parasitemia, clinical manifestation, and infection outco

124 ol parasite replication, resulted in similar parasitemia compared with control mice.

125 -87%) vaccinated volunteers remained without parasitemia compared with none of six nonvaccinated cont

126 3%) of six (95% CI, 36-99%) remained without parasitemia compared with none of six nonvaccinated cont

127 en associated with a lower risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ

128 undetectable viral load had a lower risk of parasitemia, compared with HIV-uninfected individuals (a

129 d a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >20

130 In malaria-endemic settings, asymptomatic parasitemia complicates the diagnosis of malaria.

131 N-gamma in mediating splenic cell apoptosis, parasitemia control, and host lethality and thus may pro

132 Plasmodium knowlesi parasitemia correlated with age (Spearman's correlation

133 False-negative RDT results with high parasitemia could be due to non-falciparum infection or

134 infected patients treated with artemisinins, parasitemia declines through so-called pitting, an innat

135 Cd47(-/-) mice displayed significantly lower parasitemia, decreased endothelial activation, and enhan

136 >/=37.5 degrees C and Plasmodium falciparum parasitemia density of >2500 parasites per cubic millime

137 Microscopic parasitemia developed in 22 individuals, and 21 in vitro

138 The ratio of gametocytemia to asexual parasitemia did not differ between acute and recurrent i

139 The prevalence and density of malaria parasitemia did not differ by treatment group at any of

140 prim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of

141 y of isolates were polyclonal, but recurrent parasitemias displayed fewer variants compared to initia

142 rited traits, and find evidence that malaria parasitemia does contribute to the pathogenesis of retin

143 In patients with recurrent parasitemia, drug level and genotyping using microsatell

144 zing antibodies were associated with lack of parasitemia during follow up, suggesting a role in prote

145 ely to experience microscopically detectable parasitemia during follow-up (relative risk, 11.25; 95%

146 patic activin B was also upregulated at peak parasitemia during infection with Plasmodium chabaudi Co

147 rious impact of submicroscopic P. falciparum parasitemia during pregnancy on multiple pregnancy outco

148 ted with P. berghei Anka displayed increased parasitemia, earlier mortality, enhanced leukocyte-endot

149 However, there was a high risk of recurrent parasitemia following AL treatment, which was significan

150 1 (55%) vaccinated subjects remained without parasitemia following CHMI 21 weeks after immunization.

151 ured by the rate of exponential clearance of parasitemia following treatment.

152 476 patients (162 with concurrent falciparum parasitemia) from Indonesia were evaluable.

153 on, all mice in this group had no detectable parasitemia, gained as much weight as the uninfected con

154 verity criteria in knowlesi malaria included parasitemia >100 000/microL (n = 18), jaundice (n = 20),

155 parasitemia >20 000/microL, and 28-fold with parasitemia >100 000/microL.

156 vere knowlesi malaria increased 11-fold with parasitemia >20 000/microL, and 28-fold with parasitemia

157 qPCR method for the detection of low-density parasitemias (>20 parasites/ml) was developed and valida

158 ad and age; those with the highest levels of parasitemia had a survival rate of 83%.

159 Plasmodium parasitemia had no impact on EVD outcomes.

160 Overall median (interquartile range [IQR]) parasitemia half-life (half-life) was 6.03 (4.89-7.28) h

161 visceral leishmaniasis elimination campaigns.Parasitemia has been considered the main determinant of

162 ars, cases of severe and high-level P. vivax parasitemia have been reported, challenging the assumpti

163 Individuals with asymptomatic parasitemia have clinical immunity, restricting parasite

164 We assessed the kinetics of parasitemia in 112 volunteers infected with blood-stage

165 xamined following drug-mediated clearance of parasitemia in 94 adults and 95 children in an area of h

166 eers are then monitored daily for peripheral parasitemia in a hotel setting with 24-hour access to a

167 showed significant trypanocidal activity on parasitemia in a murine model of acute Chagas disease.

168 from both clinical malaria and high-density parasitemia in a prospective longitudinal study of child

169 e-stimulated monocytes in vitro and reducing parasitemia in a rodent model of experimental cerebral m

170 stinguishes severe malaria from coincidental parasitemia in African children in a moderate-to-high tr

171 ub-Saharan Africa, the prevalence of malaria parasitemia in blood donors varies from 0.6% to 50%.

172 nhibitor of HO-1 activity increased T. cruzi parasitemia in blood.

173 ger children (P = .0001), and the decline in parasitemia in children aged 1.5-4 years often started 6

174 ction, but it increased disease severity and parasitemia in mice infected with Plasmodium chabaudi AS

175 ast, 11beta-HSD1 deficiency rather decreased parasitemia in mice infected with the reticulocyte-restr

176 lectivity and potency, suppressing >/= 99.8% parasitemia in mice when administered orally at 25 mg/kg

177 parasite DNA/RNA contributed to a decline of parasitemia in N67-infected mice.

178 n reaction (PCR) and microscopy detection of parasitemia in order to understand parasite growth rates

179 atients with cerebral malaria and those with parasitemia in other organs.

180 ods were compared for sensitive detection of parasitemia in P. falciparum cultures.

181 s) with bound platelets during the ascending parasitemia in Plasmodium chabaudi- and Plasmodium bergh

182 rsons with blood-stage Plasmodium falciparum parasitemia in the absence of symptoms are considered to

183 t possibly enabling exposed women to control parasitemia in the face of pregnancy-induced Th2 polariz

184 The prevalence of malaria parasitemia in the study population was 77.8% (1447/1860

185 ite burden, preventing development of patent parasitemia in vivo.

186 Secondary outcomes included malaria parasitemia (in peripheral, placental, cord blood specim

187 The parasitemia incidence was 42.0 cases per 100 person-year

188 AhR KO mice displayed significantly reduced parasitemia, inflammation, and fibrosis of the myocardiu

189 ts on the acute phase of Chagas disease gave parasitemia inhibition values twice those of benznidazol

190 olo-rusticyanin to infected cells results in parasitemia inhibition, but negligible effects on parasi

191 Plasmodium species parasitemia is associated with an increase in the probab

192 Residual submicroscopic parasitemia is common after ACT and is associated with a

193 Asymptomatic parasitemia is common even in areas of low seasonal mala

194 malaria-endemic areas, Plasmodium falciparum parasitemia is common in apparently healthy children and

195 to stimulate T cells, recovering only as the parasitemia is controlled.

196 Importantly, if exposure to blood-stage parasitemia is extended, blood-stage parasites induce cr

197 Subpatent and asymptomatic multispecies parasitemia is relatively common in North Sumatera, so P

198 ptomatic, submicroscopic Plasmodium knowlesi parasitemia is unknown.

199 ses, particularly in those with high asexual parasitemia, is likely the most important strategy for i

200 ether subjects experienced rises or falls in parasitemia level after treatment.

201 obtained after exposure to bites, as did the parasitemia level and the number of monocytes in the cir

202 alarials were unable to prevent rises in the parasitemia level in the first 12 hours.

203 acting but not slow-acting drugs reduced the parasitemia level independent of when treatment was admi

204 udes the highly variable lag phase, when the parasitemia level may increase, remain constant, or decr

205 nd without any chemical or immunolabeling, a parasitemia level of fewer than ten parasites per microl

206 n the parasite growth cycle, and whether the parasitemia level rose or fell in the first 12 or 24 hou

207 The parasitemia level was measured by quantitative polymeras

208 tude of decreases in RBC was a reflection of parasitemia level, but low reticulocytosis was evident d

209 nalysis showed that the plasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a s

210 icity for the PLS-DA was found to be 98% for parasitemia levels >0.5%, but a rather low sensitivity o

211 deficient for galectin-3 have elevated blood parasitemia levels and impaired cytokine production duri

212 n less than 3 seconds (enabling detection at parasitemia levels as low as 0.0005%).

213 -negative LAMP results involved samples with parasitemia levels detectable by 3-well nested PCR but v

214 We found that B. microti reaches high parasitemia levels during the first week of infection in

215 , 7, and 10 induced a remarkable decrease in parasitemia levels in acute phase and the parasitemia re

216 bioencapsulating the artemisinin reduced the parasitemia levels in challenged mice in comparison with

217 1 plasma samples from patients with malaria (parasitemia levels of 0.0037 to 3.4%).

218 cant differences in platelet counts or blood parasitemia levels were observed between VWF(-/-) and WT

219 e immuno-polymerase chain reaction (PCR), to parasitemia limits of 0.02 parasite/microL and 0.78 para

220 ute detection limit was found to be 0.00001% parasitemia (<1 parasite/muL of blood; p < 0.008) for cu

221 Residual parasitemia may also have consequences for individual pa

222 reas because encephalopathy in patients with parasitemia may have another cause.

223 c cell deformability sensor for quantitative parasitemia measurement and stage determination for Plas

224 uantitative polymerase chain reaction (qPCR) parasitemia monitoring can discriminate between vaccine

225 T. cruzi (Y strain) and determined levels of parasitemia, myocardial inflammation and fibrosis, expre

226 od, to determine the risk of Plasmodium spp. parasitemia (n=8390) and Plasmodium falciparum HRP-2 (Pf

227 tyre Coma Score </= 2, Plasmodium falciparum parasitemia, no other identifiable cause for coma) were

228 The improved control of parasitemia observed in the absence of CXCL10-mediated t

229 Parasitemia occurs frequently during pregnancy, but rout

230 romising compound (13) showed a reduction in parasitemia of 96% when dosed at 30 mg/kg orally once a

231 The cumulative risk of recurrent parasitemia on day 42 after initiation of treatment, una

232 PM experienced a lower incidence of malaria parasitemia or clinical malaria than the other 3 groups:

233 The incidence of malaria parasitemia or clinical malaria was about 2 times higher

234 The incidence of all episodes of malaria parasitemia or clinical malaria was very similar among 3

235 ed for triggers such as high-density asexual parasitemia or drug treatment.

236 aria but safe and at least similar regarding parasitemia or placental malaria and birth outcomes.

237 T. cruzi-specific B cells failed to control parasitemia or prevent death.

238 cruzi, even before they developed detectable parasitemia or seroconversion.

239 Malaria parasitemia persists in humans at levels that optimize t

240 Other outcomes included malaria incidence, parasitemia, placental malaria, anemia, and infants' bir

241 controlled HIV infection had a lower risk of parasitemia, presumably reflecting access to HIV care.

242 resulted in progressive increases in malaria parasitemia prevalence and burden.

243 (MSP1) injected into BALB/c mice during peak parasitemia proliferate poorly, and very few cells produ

244 low for label-free, rapid and cost-effective parasitemia quantification and stage determination for m

245 More than 30,000 RBCs can be analyzed for parasitemia quantification in under 1min with a throughp

246 glucose and urea analytes along with malaria parasitemia quantification using one spectrum obtained f

247 levels (r = 0.69; p = 0.01) and weakly with parasitemia (r = -0.38; p = 0.006).

248 , at dose of 30 mg daily for 3 days, cleared parasitemia rapidly in adults with uncomplicated P. viva

249 in parasitemia levels in acute phase and the parasitemia reactivation following immunosuppression, an

250 Rates, quantity, and timing of parasitemia rebound following CTX remain undefined.

251 wed significant in vivo efficacy with 73% of parasitemia reduction in a mouse model.

252 l genotypes of those who developed recurrent parasitemia, representing the first time P. vivax varian

253 as associated with reduced rates of maternal parasitemia (risk ratio [RR], 0.47 [95% CI 0.27-0.82]; p

254 g vitamin A were less likely to present with parasitemia (RR=0.46, 95% CI=0.39-0.54) and antigenemia

255 More than half of the recurrent parasitemias sampled displayed identical or highly relat

256 nfection and developed a 9.3-fold lower peak parasitemia than their wild-type (WT) counterparts.

257 T-bet-deficient (Tbx21(-/-)) mice had higher parasitemia than wild type controls did during the ECM p

258 mmonest cause of severe malaria at QEH, with parasitemia the major risk factor for severity.

259 r T cell responses are required for limiting parasitemia, these responses need to be switched off by

260 The timing of, parasitemia threshold of, and contribution of apoptosis

261 t of HEIs (n = 471) were tested for malarial parasitemia using dried blood spots from 12, 24, and 36

262 ate by CellaVision was 100% (23/23) when the parasitemia was >/=2.5%.

263 Prevalence of parasitemia was 16.7% in the CMX group vs 28% in the IPT

264 The detection rate for <0.1% parasitemia was 63% (15/24).

265 The community prevalence of parasitemia was 83.8% (95% confidence interval [CI], 82.

266 Residual parasitemia was associated with a 2-fold longer duration

267 Having asymptomatic malaria parasitemia was associated with a 40% increase in respir

268 High asexual parasitemia was associated with an increased risk of gam

269 sma piperaquine concentration at the time of parasitemia was associated with increasing pfmdr1 86Y pr

270 ighest risk for fetal anemia, and density of parasitemia was correlated with the decrease in cord Hb.

271 Residual parasitemia was detected by qPCR in 31.8% (95% confidenc

272 re likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebo

273 a remarkable decrease in the reactivation of parasitemia was found in the chronic phase for immunodef

274 -treated bed nets, the prevalence of malaria parasitemia was high across all ages, peaking in school-

275 Plasmodium falciparum parasitemia was less frequent than in non-BWF controls,

276 Parasitemia was monitored by quantitative real-time poly

277 Parasitemia was not affected by ET-1 treatment.

278 Lower Leishmania parasitemia was observed after antileishmanial and antir

279 ce during the acute phase of infection, when parasitemia was rapidly rising.

280 Parasitemia was reduced by over 90% in P. berghei infect

281 The risk of recurrent parasitemia was significantly lower among children takin

282 P chabaudi primary and secondary parasitemia was similar in mice depleted of platelets by

283 Parasitemia was successfully managed with preemptive tre

284 Children with residual parasitemia were also significantly more likely to exper

285 ing a weighted proportion, and predictors of parasitemia were identified using a multivariate Poisson

286 Risks of recurrent parasitemia were lower with AS/AQ at all 3 sites (overal

287 ost ABO blood group, reticulocyte count, and parasitemia were not correlated with P vivax rosetting.

288 . vivax malaria, but high rates of recurrent parasitemia were noted with both drugs.

289 gative CM that would be prevented if malaria parasitemia were to be eliminated is estimated to be 0.9

290 in T. cruzi-infected infants correlated with parasitemia, whereas the plasma levels of IL-17A, IL-17F

291 he disease pathology is a consequence of the parasitemia which develops through cyclical replication

292 f) proliferation and strongly decreased peak parasitemia, which is consistent with improved Teff func

293 egies depend on identifying individuals with parasitemia, who may be asymptomatic but retain the abil

294 s with low (LPVM) and moderately-high (MPVM) parasitemia with healthy community controls.

295 tion of (1) CPT and (2) asymptomatic malaria parasitemia with respiratory and diarrheal morbidity in

296 crosatellite markers to reclassify recurrent parasitemias with a different genotype as non-treatment

297 All volunteers developed blood-stage parasitemia, with no impact of the vaccine on PMR.

298 Recurrent parasitemia within 28 days was common following AL treat

299 Primary outcomes were risks of recurrent parasitemia within 28 days, with or without adjustment t

300 hat asymptomatic subjects with P. falciparum parasitemia would differentially recognize a subset of P